ANIK News 48.15 05/30/2014 04:26:36 Anika Therapeutics Inc (
Post# of 273254
Posted On: 05/30/2014 5:26:27 AM
Anika Therapeutics Inc (ANIK) 48.15 $ANIK
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Stocks Up At Midday; Twitter Climbs On Upgrade
at Investor's Business Daily - Thu May 29, 11:00AM CDT
Stocks were holding on to modest gains at midday Thursday even after revised GDP figures showed that the economy contracted more than expected in the first quarter. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2% to a fresh record high and the Dow...
34.7% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Thu May 29, 9:10AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 34.74% as of today's recent price of $46.72.
Anika Therapeutics Has Returned 31.4% Since SmarTrend Recommendation (ANIK)
Comtex SmarTrend(R) - Wed May 21, 4:51PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 31.39% as of today's recent price of $45.56.
Global Hyaluronic Acid Products Market Product Trends and Forecasts, 2019: Single-Injection, Three-Injection Cycle and Five-Injection Cycle Analysis
M2 - Wed May 14, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snvprr/hyaluronic_acid) has announced the addition of the "Hyaluronic Acid Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. Hyaluronic acid (HA) is a unique non-sulfated glycosaminoglycan, distributed throughout the body in connective tissues, epithelial and neural tissues. Hyaluronic acid contributes significantly to cell proliferation and migration and is observed to be an integral component of the extracellular matrix. Hyaluronic acid has wide number of applications such as orthopedic surgery, rheumatology, ophthalmology, otolaryngology, dermatology and plastic surgery, wound healing and drug delivery. Hyaluronic acid products are segmented on the basis of treatment regimen into single-injection, three-injection cycle and five-injection cycle products. In addition, HA injectable can be utilized in a range of applications such as osteoarthritis, dermal fillers, ophthalmic surgery and vesicoureteral reflux (VUX). The major factors driving this market are increasing geriatric population globally, high awareness about anti-aging procedures, patient's preference for the treatment with minimum side-effects and rising demand for minimally invasive surgical procedures. In products segment, five-injection cycle products is the largest marketsegment and single-injection market segment is growing with highest CAGR during forecast period from 2013 to 2019. Hyaluronic acid products market is observing a global shift in usage of five-injection cycle to single-injection cycle treatment as there has been a considerable change in preference of patients towards short duration treatment. This shift in preference is mainly related to convenience of patients as they try to avoid side-effects such as redness, inflammation and itching experienced after every treatment and five-injection cycle is a prolonged treatment compared to single-injection. Dermal fillers is the largest market closely followed by osteoarthritis market and vesicoureteral reflux (VUR) applications market. VUR application market for hyaluronic acid products is growing at a highest CAGR during the forecast period from 2013 to 2019. The segment is mainly driven by aging population, high demand for minimally invasive surgical treatments and high awareness about beauty enhancements. Report Scope Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Hyaluronic Acid Products Market, by Geography - North America - Europe - Asia-Pacific - Rest of the World (RoW) Companies Mentioned - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sn...ronic_acid
Biotech Companies Report Quarterly Financial Results - Analyst Notes on Intrexon, Acorda, Anika, Sangamo and Spectrum
PR Newswire - Wed May 14, 8:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intrexon Corporation (NYSE: XON), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Anika Therapeutics, Inc. (NASDAQ: ANIK), Sangamo Biosciences, Inc. (NASDAQ: SGMO) and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2531-100free.
IBD 50 High-Growth Shares Remain In Correction
at Investor's Business Daily - Fri May 09, 5:55PM CDT
Weather across America may have more or less returned to normal. Thoughts of winter are drifting further behind. But there are still few signs of a spring thaw in the market for high-growth, high-priced stocks. While the Dow Jones industrial average...
Anika Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (ANIK)
Comtex SmarTrend(R) - Wed May 07, 9:42AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 31.10% as of today's recent price of $45.46.
Stocks Finish Higher After Early Sell-Off
at Investor's Business Daily - Mon May 05, 3:21PM CDT
Stocks finished modestly higher Monday after opening down on jitters over violence in Ukraine and weak Chinese factory data. The Nasdaq rose 0.3%, the S&P 500 0.2% and the Dow Jones industrial average 0.1%. Volume was lower across the board,...
Insider Trading Alert - ANIK, TRLA And AMED Traded By Insiders
at The Street - Mon May 05, 9:15AM CDT
Stocks with insider trader activity include ANIK, TRLA and AMED
5 Stocks Ready to Break Out
at The Street - Fri May 02, 12:53PM CDT
These stocks look poised to break out and trade higher from current levels.
Stocks Close Mixed; Nasdaq Up For Third Straight Day
at Investor's Business Daily - Thu May 01, 3:20PM CDT
Stocks gave up early gains Thursday to finish mixed, with the Nasdaq hanging on to a narrow gain. The day marked the third straight advance for the Nasdaq. The Nasdaq rose 0.3%; the S&P 500 was down a hair and the Dow Jones industrial average fell...
Stocks Turn Mixed: Valeant Retakes 50-Day Line
at Investor's Business Daily - Thu May 01, 12:35PM CDT
Stocks lost steam and turned mixed Thursday afternoon, as indexes wavered amid a barrage of earnings reports and mixed economic data. The Nasdaq was up 0.6% after rising 0.8% earlier. The S&P 500 edged up 0.1%. But the Dow Jones industrial average...
4 Big-Volume Stocks in Breakout Territory
at The Street - Thu May 01, 8:18AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Stocks Rise In Higher Volume; Anika Jumps On Earnings
at Investor's Business Daily - Wed Apr 30, 4:04PM CDT
Stocks rose Wednesday, with the Dow Jones industrial average closing at a new all-time high, after the Federal Reserve expressed optimism about the economy. The Dow, the S&P 500 and the Nasdaq each climbed 0.3% in the stock market today. The Nasdaq...
Shares of ANIK Up 17.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 30, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 2 months, Anika Therapeutics has returned 17.16% as of today's recent price of $40.63.
Anika Therapeutics achieves higher net income of USD15.0m in Q1 2014
M2 - Wed Apr 30, 5:18AM CDT
Tissue protection company Anika Therapeutics (NasdaqGS:ANIK) stated on Tuesday its net income of USD15.0m (USD0.97 per diluted share) for the first quarter ended 31 March 2014.
ANIKA THERAPEUTICS'
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
ANIKA THERAPEUTICS' (ANIK) Q1 EPS soared to 97 cents vs. 20 cents a year ago. The biotech's revenue jumped 123% to $34 mil, above views. Shares rose 5.1% to 42.99.
Anika Therapeutics Reports First Quarter 2014 Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
--Total Revenue Grows 123% to $34 Million
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Stocks Up At Midday; Twitter Climbs On Upgrade
at Investor's Business Daily - Thu May 29, 11:00AM CDT
Stocks were holding on to modest gains at midday Thursday even after revised GDP figures showed that the economy contracted more than expected in the first quarter. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2% to a fresh record high and the Dow...
34.7% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Thu May 29, 9:10AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 34.74% as of today's recent price of $46.72.
Anika Therapeutics Has Returned 31.4% Since SmarTrend Recommendation (ANIK)
Comtex SmarTrend(R) - Wed May 21, 4:51PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 31.39% as of today's recent price of $45.56.
Global Hyaluronic Acid Products Market Product Trends and Forecasts, 2019: Single-Injection, Three-Injection Cycle and Five-Injection Cycle Analysis
M2 - Wed May 14, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snvprr/hyaluronic_acid) has announced the addition of the "Hyaluronic Acid Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. Hyaluronic acid (HA) is a unique non-sulfated glycosaminoglycan, distributed throughout the body in connective tissues, epithelial and neural tissues. Hyaluronic acid contributes significantly to cell proliferation and migration and is observed to be an integral component of the extracellular matrix. Hyaluronic acid has wide number of applications such as orthopedic surgery, rheumatology, ophthalmology, otolaryngology, dermatology and plastic surgery, wound healing and drug delivery. Hyaluronic acid products are segmented on the basis of treatment regimen into single-injection, three-injection cycle and five-injection cycle products. In addition, HA injectable can be utilized in a range of applications such as osteoarthritis, dermal fillers, ophthalmic surgery and vesicoureteral reflux (VUX). The major factors driving this market are increasing geriatric population globally, high awareness about anti-aging procedures, patient's preference for the treatment with minimum side-effects and rising demand for minimally invasive surgical procedures. In products segment, five-injection cycle products is the largest marketsegment and single-injection market segment is growing with highest CAGR during forecast period from 2013 to 2019. Hyaluronic acid products market is observing a global shift in usage of five-injection cycle to single-injection cycle treatment as there has been a considerable change in preference of patients towards short duration treatment. This shift in preference is mainly related to convenience of patients as they try to avoid side-effects such as redness, inflammation and itching experienced after every treatment and five-injection cycle is a prolonged treatment compared to single-injection. Dermal fillers is the largest market closely followed by osteoarthritis market and vesicoureteral reflux (VUR) applications market. VUR application market for hyaluronic acid products is growing at a highest CAGR during the forecast period from 2013 to 2019. The segment is mainly driven by aging population, high demand for minimally invasive surgical treatments and high awareness about beauty enhancements. Report Scope Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Hyaluronic Acid Products Market, by Geography - North America - Europe - Asia-Pacific - Rest of the World (RoW) Companies Mentioned - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sn...ronic_acid
Biotech Companies Report Quarterly Financial Results - Analyst Notes on Intrexon, Acorda, Anika, Sangamo and Spectrum
PR Newswire - Wed May 14, 8:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intrexon Corporation (NYSE: XON), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Anika Therapeutics, Inc. (NASDAQ: ANIK), Sangamo Biosciences, Inc. (NASDAQ: SGMO) and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2531-100free.
IBD 50 High-Growth Shares Remain In Correction
at Investor's Business Daily - Fri May 09, 5:55PM CDT
Weather across America may have more or less returned to normal. Thoughts of winter are drifting further behind. But there are still few signs of a spring thaw in the market for high-growth, high-priced stocks. While the Dow Jones industrial average...
Anika Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (ANIK)
Comtex SmarTrend(R) - Wed May 07, 9:42AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 31.10% as of today's recent price of $45.46.
Stocks Finish Higher After Early Sell-Off
at Investor's Business Daily - Mon May 05, 3:21PM CDT
Stocks finished modestly higher Monday after opening down on jitters over violence in Ukraine and weak Chinese factory data. The Nasdaq rose 0.3%, the S&P 500 0.2% and the Dow Jones industrial average 0.1%. Volume was lower across the board,...
Insider Trading Alert - ANIK, TRLA And AMED Traded By Insiders
at The Street - Mon May 05, 9:15AM CDT
Stocks with insider trader activity include ANIK, TRLA and AMED
5 Stocks Ready to Break Out
at The Street - Fri May 02, 12:53PM CDT
These stocks look poised to break out and trade higher from current levels.
Stocks Close Mixed; Nasdaq Up For Third Straight Day
at Investor's Business Daily - Thu May 01, 3:20PM CDT
Stocks gave up early gains Thursday to finish mixed, with the Nasdaq hanging on to a narrow gain. The day marked the third straight advance for the Nasdaq. The Nasdaq rose 0.3%; the S&P 500 was down a hair and the Dow Jones industrial average fell...
Stocks Turn Mixed: Valeant Retakes 50-Day Line
at Investor's Business Daily - Thu May 01, 12:35PM CDT
Stocks lost steam and turned mixed Thursday afternoon, as indexes wavered amid a barrage of earnings reports and mixed economic data. The Nasdaq was up 0.6% after rising 0.8% earlier. The S&P 500 edged up 0.1%. But the Dow Jones industrial average...
4 Big-Volume Stocks in Breakout Territory
at The Street - Thu May 01, 8:18AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Stocks Rise In Higher Volume; Anika Jumps On Earnings
at Investor's Business Daily - Wed Apr 30, 4:04PM CDT
Stocks rose Wednesday, with the Dow Jones industrial average closing at a new all-time high, after the Federal Reserve expressed optimism about the economy. The Dow, the S&P 500 and the Nasdaq each climbed 0.3% in the stock market today. The Nasdaq...
Shares of ANIK Up 17.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 30, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 2 months, Anika Therapeutics has returned 17.16% as of today's recent price of $40.63.
Anika Therapeutics achieves higher net income of USD15.0m in Q1 2014
M2 - Wed Apr 30, 5:18AM CDT
Tissue protection company Anika Therapeutics (NasdaqGS:ANIK) stated on Tuesday its net income of USD15.0m (USD0.97 per diluted share) for the first quarter ended 31 March 2014.
ANIKA THERAPEUTICS'
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
ANIKA THERAPEUTICS' (ANIK) Q1 EPS soared to 97 cents vs. 20 cents a year ago. The biotech's revenue jumped 123% to $34 mil, above views. Shares rose 5.1% to 42.99.
Anika Therapeutics Reports First Quarter 2014 Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
--Total Revenue Grows 123% to $34 Million
(0)
(0)Scroll down for more posts ▼